BOSTON, July 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on August 4, 2016, to discuss the financial results for the second quarter ended June 30, 2016. The call details are as follows:
Thursday, August 4, 2016
8:30 a.m. EDT
Toll free: (866) 374-4635 (U.S.), (855) 669-9657 (Canada), or
The teleconference replay will be available at approximately one hour after completion through Thursday, August 11, 2016, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10089864.
The archived webcast will be available for one year via the aforementioned URLs.
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage novel intravaginal drug delivery technologies. These R&D programs are funded in part by cash flows from Crinone® (progesterone gel) and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development, analytical characterization, and clinical trials manufacturing for clients. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.